RESEARCH ANTIBODIES MARKET ANALYSIS

Research Antibodies Market Size and Trends

Global research antibodies market is estimated to be valued at USD 11.91 Bn in 2024 and is expected to reach USD 18.60 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global Research Antibodies Market Trend-

There are several variables that propel the market for research antibodies. Proteomics and genomics research is on the rise, as are research academies and industrial partnerships, as well as increased R&D spending. Research antibodies play a crucial role in biopharmaceutical and pharmaceutical research since they are necessary for understanding the origins of diseases and for examining biological processes. Thus, the market is expanding due to expanding research on stem cells and neurobiology worldwide, as well as product advancements and company collaboration.

Increasing research and development activities

Global research antibodies market growth is driven by increased research and development activities. Global research antibodies market growth is driven by increased investment in research and development, heightened collaboration between research institutions and industries, and surge in proteomics and genomics studies. Research antibodies are integral to biopharmaceutical and pharmaceutical research, facilitating the exploration of biological processes and the understanding of disease mechanisms. With expanding stem cell and neurobiology research worldwide, coupled with continuous product innovations and industry collaborations, the market is witnessing significant growth. For instance, in March 2022, according to the study published by Journal eLife, researchers from the University of Washington, the Max Planck Institute for Dynamics and Self-Organization, and the University of Cologne focused on broadly neutralizing antibodies (bNAbs). The research highlighted the potential of bNAbs in treating HIV while mitigating the risk of viral transmission. The study underscores the importance of computational approaches in selecting optimal combinations of bNAbs based on viral genetics to enhance HIV treatment efficacy and prevent viral escape.

Growing Investments & Increasing product launches

Increased investments from both public and private sectors in life science R&D can drive the research antibodies market growth. This is fueled by the recognition of the importance of basic research in fields like immunology, cancer biology, genetics, and neuroscience. The development of novel antibody-based therapeutics and diagnostics is attracting substantial capital, leading to growing demand for research antibodies in academic and industry labs. This trend is supported by sophisticated core facilities in leading research institutions, indicating sustained growth potential for the market. Product approvals by industry participants can drive the research antibody market growth during the forecast period. Tepezza (TM) (teprotumumab-trbw), a therapeutic monoclonal antibody for the treatment of thyroid eye disease (TED), was approved by the U.S. Food and Drug Administration on January 21, 2020. Horizon Therapeutics plc is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines, and it had developed Tepezza (TM) (teprotumumab-trbw). TED is an unusual autoimmune disorder that is severe, progressive, and potentially blinding. It is characterized by pain, inflammation, deformity of the face, diplopia (double vision), proptosis (eye bulging), and blurred vision. The FDA (Food and Drug Administration) in the U.S. had approved Tepezza as the sole drug for TED patients.